Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:CASNumber |
1446144-04-2
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:hasMolecularFormula |
C22H19F3N4O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
GSK583
|
| gptkbp:inhibitedBy |
gptkb:RIPK2
|
| gptkbp:IUPACName |
N-(6-(tert-butyl)-1,3-benzothiazol-2-yl)-2-(trifluoromethyl)benzamide
|
| gptkbp:mechanismOfAction |
RIPK2 kinase inhibitor
|
| gptkbp:potentialTherapeuticArea |
inflammatory diseases
|
| gptkbp:synonym |
GSK-583
|
| gptkbp:usedIn |
preclinical research
|
| gptkbp:bfsParent |
gptkb:RIPK2
|
| gptkbp:bfsLayer |
8
|